新疆地区甲状腺乳头状癌中BRAF V600E基因的表达及意义

发布时间：2018-05-09 18:50

  本文选题：甲状腺肿瘤 + 乳头状癌　； 参考：《临床与实验病理学杂志》2016年08期

【摘要】：目的探讨新疆地区BRAF V600E基因点突变在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中的表达,及其与临床病理特征的关系。方法收集原发性PTC 178例,石蜡包埋组织经QIAGEN试剂盒提取DNA,经Taq Man探针荧光定量PCR技术检测PTC中BRAF基因点突变。结果 178例原发性PTC中BRAF V600E基因点突变142例,突变率为79.8%(142/178)。患者年龄(≥45岁)、肿瘤直径(≤1 cm)、被膜外侵犯BRAF V600E基因点突变率高(P均0.05),而BRAF V600E基因点突变与患者性别、多灶性及淋巴结转移灶和肿瘤部位均无相关性(P均0.05)。结论新疆地区PTC中BRAF V600E基因点突变与临床病理特征密切相关,且具有一定特异性,可作为PTC诊断提供依据。
[Abstract]:Objective to investigate the expression of BRAF V600E gene point mutation in papillary thyroid carcinoma of thyroid and its relationship with clinicopathological features. Methods A total of 178 cases of primary PTC were collected. DNA was extracted from paraffin embedded tissue by QIAGEN kit. The point mutation of BRAF gene in PTC was detected by Taq Man probe fluorescence quantitative PCR technique. Results among 178 cases of primary PTC, 142 cases had point mutation of BRAF V600E gene, the mutation rate was 79.8% and 142 / 178%. Age (鈮，

本文编号：1867012